Jimi Huh1, Yoonseok Choi2, Dong-Cheol Woo2, Nieun Seo1, Bohyun Kim1, Chang Kyung Lee2, In Seong Kim3, Dominik Nickel4, Kyung Won Kim5,6. 1. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. 2. Bioimaging Center, Asan Institute for Life Sciences, Asan Medical Center, 88 Olympic-ro, Seoul, Korea. 3. Siemens Healthcare, 23 Chungjung-ro, Seoul, Korea. 4. Siemens Healthcare, Henkestrabe 127, Erlangen, Germany. 5. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. medimash@gmail.com. 6. Bioimaging Center, Asan Institute for Life Sciences, Asan Medical Center, 88 Olympic-ro, Seoul, Korea. medimash@gmail.com.
Abstract
OBJECTIVES: To evaluate the feasibility of test-bolus dynamic contrast-enhanced (DCE) MRI with CAIPIRINHA-VIBE for pancreatic malignancies. METHODS: Thirty-two patients underwent DCE-MRI with CAIPIRINHA-VIBE after injection of 2 mL gadolinium. From the resulting time-intensity curve (TIC), we estimated the arterial (AP) and portal venous phase (PVP) scan timing for subsequent multiphasic MRI. DCE-MRI perfusion maps were generated, and perfusion parameters were calculated. The image quality was rated on a 5-point scale (1: poor, 5: excellent). Goodness-of-fit of the TIC was evaluated by Pearson's χ2 test. RESULTS: Test-bolus DCE-MRIs with high temporal (3 s) and spatial resolution (1 × 1 × 4 mm3) were acquired with good-quality perfusion maps of Ktrans and iAUC (mean score 4.313 ± 0.535 and 4.125 ± 0.554, respectively). The mean χ2 values for fitted TICs were 0.115 ± 0.082 for the pancreatic parenchyma and 0.784 ± 0.074 for pancreatic malignancies, indicating an acceptable goodness-of-fit. Test-bolus DCE-MRI was highly accurate in estimating the proper timing of AP (90.6 %) and PVP (100 %) of subsequent multiphasic MRI. Between pancreatic adenocarcinomas and neuroendocrine tumours, there were significant differences in the Ktrans (0.073 ± 0.058 vs. 0.308 ± 0.062, respectively; p = 0.007) and iAUC (1.501 ± 0.828 vs. 3.378 ± 0.378, respectively; p = 0.045). CONCLUSIONS: Test-bolus DCE-MRI using CAIPIRINHA-VIBE is feasible for incorporating perfusion analysis of pancreatic tumours into routine multiphasic MRI. KEY POINTS: • Test-bolus DCE-MRI using CAIPIRINHA-VIBE is feasible for perfusion analysis of pancreatic tumours. • CAIPIRINHA-VIBE enables DCE-MRI with high temporal and spatial resolution. • Test-bolus DCE-MRI is highly accurate in estimating the proper timing of multiphasic MRI.
OBJECTIVES: To evaluate the feasibility of test-bolus dynamic contrast-enhanced (DCE) MRI with CAIPIRINHA-VIBE for pancreatic malignancies. METHODS: Thirty-two patients underwent DCE-MRI with CAIPIRINHA-VIBE after injection of 2 mL gadolinium. From the resulting time-intensity curve (TIC), we estimated the arterial (AP) and portal venous phase (PVP) scan timing for subsequent multiphasic MRI. DCE-MRI perfusion maps were generated, and perfusion parameters were calculated. The image quality was rated on a 5-point scale (1: poor, 5: excellent). Goodness-of-fit of the TIC was evaluated by Pearson's χ2 test. RESULTS: Test-bolus DCE-MRIs with high temporal (3 s) and spatial resolution (1 × 1 × 4 mm3) were acquired with good-quality perfusion maps of Ktrans and iAUC (mean score 4.313 ± 0.535 and 4.125 ± 0.554, respectively). The mean χ2 values for fitted TICs were 0.115 ± 0.082 for the pancreatic parenchyma and 0.784 ± 0.074 for pancreatic malignancies, indicating an acceptable goodness-of-fit. Test-bolus DCE-MRI was highly accurate in estimating the proper timing of AP (90.6 %) and PVP (100 %) of subsequent multiphasic MRI. Between pancreatic adenocarcinomas and neuroendocrine tumours, there were significant differences in the Ktrans (0.073 ± 0.058 vs. 0.308 ± 0.062, respectively; p = 0.007) and iAUC (1.501 ± 0.828 vs. 3.378 ± 0.378, respectively; p = 0.045). CONCLUSIONS: Test-bolus DCE-MRI using CAIPIRINHA-VIBE is feasible for incorporating perfusion analysis of pancreatic tumours into routine multiphasic MRI. KEY POINTS: • Test-bolus DCE-MRI using CAIPIRINHA-VIBE is feasible for perfusion analysis of pancreatic tumours. • CAIPIRINHA-VIBE enables DCE-MRI with high temporal and spatial resolution. • Test-bolus DCE-MRI is highly accurate in estimating the proper timing of multiphasic MRI.
Entities:
Keywords:
Feasibility studies; Magnetic resonance imaging; Neoplasms; Pancreas; Perfusion imaging
Authors: J H Naish; C E Hutchinson; A Caunce; C Roberts; J C Waterton; P D Hockings; C J Taylor; G J M Parker Journal: J Magn Reson Imaging Date: 2010-09 Impact factor: 4.813
Authors: M Fatih Akisik; Kumaresan Sandrasegaran; Guixue Bu; Chen Lin; Gary D Hutchins; Elena G Chiorean Journal: Radiology Date: 2010-06-01 Impact factor: 11.105
Authors: M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman Journal: Br J Radiol Date: 2003 Impact factor: 3.039
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Khoschy Schawkat; Michael Ith; Andreas Christe; Wolfgang Kühn; Yojena Chittazhathu; Lauren Bains; Val Murray Runge; Johannes T Heverhagen Journal: Eur Radiol Date: 2018-01-04 Impact factor: 5.315